Keywords: AE, adverse event; CAP, controlled attenuation parameter; CDSCO, Central Drugs Standard Control Organisation; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PPAR, peroxisome proliferator–activated receptors; TG, triglyceride.